What is the primary challenge in DART studies for immune checkpoint inhibitors?

A: The principal challenge is managing the risk of on-target, off-tumor toxicity resulting from exaggerated pharmacology. Modulating the maternal immune system, which is naturally calibrated to tolerate the fetus, requires study designs that can detect disruptions to maternal immune tolerance, placental function, and fetal development.

How is a relevant species selected for a human-specific monoclonal antibody?

A: Species selection is based on target sequence homology, binding affinity, and functional activity. If no pharmacologically relevant species exists, regulatory guidance supports the use of a surrogate antibody in a relevant species or testing the human antibody in a genetically engineered model (e.g., a transgenic model expressing the human target).

When is an enhanced pre- and postnatal development (eF-PND) study required?

A: An eF-PND study is indicated when there are concerns for functional deficits that may manifest after birth. For immune checkpoint modulators, this is a frequent requirement due to the potential impact on the development and maturation of the neonatal immune system, which continues long after parturition.

How is placental transfer assessed for a monoclonal antibody?

A: Placental transfer is typically evaluated by measuring antibody concentrations in fetal circulation at term (caesarean section) and comparing them to maternal concentrations. This data is necessary for interpreting any potential fetal or neonatal findings and assessing risk for the developing infant.

Developmental and Reproductive Toxicology (DART) programs for monoclonal antibodies targeting novel immune checkpoints demand a tailored scientific approach. Standard toxicology designs are insufficient. The core objective is to assess the potential impact of intended pharmacology: targeted immune system modulation: on maternal health, embryo-fetal viability, and postnatal development. A successful GxP study design hinges on rigorous species selection, precise evaluation of placental transfer, and the inclusion of functional endpoints relevant to immune system maturation.

Assessing developmental risk for a biologic designed to modulate the maternal immune system presents a unique set of scientific questions. The primary safety concern for immunomodulatory biologics is the potential for exaggerated pharmacology to disrupt the delicate immunological balance required for a successful pregnancy.

An effective program is built on a deep understanding of the antibody’s mechanism of action (MoA). Key considerations include:

• The specific cell types expressing the target checkpoint.

• The role of the target in maternal immune tolerance.

• Potential for antibody-mediated cellular functions like cytotoxicity or other effector mechanisms.

A forward-thinking safety strategy must account for the host immune response to the therapeutic itself. The scientific principles for evaluating pre-existing immunity to inform therapeutic design, as demonstrated in fields like AAV vector development (PMID: 32733434), are directly applicable here. Just as understanding pre-existing antibodies to a viral vector is necessary to ensure efficacy, a robust DART program must proactively assess potential immunogenicity and its impact on exposure, clearance, and safety interpretation.

Our GxP-compliant DART studies are executed within our >100,000 sq ft facility, designed to support the complex logistics of long-term biologic safety programs. By optimizing study design from the outset, we help sponsors navigate the path to a successful regulatory submission, targeting an 18-24 month IND timeline. Since 2019, programs conducted at our facilities have maintained a 100% IND success rate. (The Franklin Biolabs brand launched in 2024).

Process optimization is a key part of how we manage these complex programs efficiently.

[VIDEO: FBL-VID-02-Approved_enhanced_affordable_clip_long.mp4]

Key endpoints for an immune checkpoint mAb DART program include:

• Maternal Endpoints: Clinical observations, body weight, food consumption, immune cell population analysis (flow cytometry), and terminal histology.

• Reproductive and Fetal Endpoints: Caesarean section and litter observations, external, visceral, and skeletal fetal examinations.

• Placental Transfer: Quantification of the therapeutic in maternal and fetal serum.

• Postnatal Assessment (eF-PND): Pup viability, growth, and functional evaluations, including T-cell dependent antibody response (TDAR) assays to assess immune system competence.

We uphold the highest standards of animal welfare through our strategic partners. For example, non-human primate studies conducted with our partner Bioculture Group are performed in AAALAC-accredited facilities, with all study designs adhering to the 3Rs (Replacement, Reduction, Refinement) principles.